Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against Gram-positive cocci
Teresa M. Coque(Instituto Cajal), Barbara E. Murray(Centers for Disease Control and Prevention), Kavindra V. Singh(National University of Computer and Emerging Sciences)
Cited by 29
Related Papers
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
|Clinical Infectious Diseases|2011|4.2k
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children: Executive Summary
|Clinical Infectious Diseases|2011|1.6k
Defining and combating antibiotic resistance from One Health and Global Health perspectives
|Nature Microbiology|2019|1.2k
The CTX-M β-lactamase pandemic
|Current Opinion in Microbiology|2006|1.1k
What is a resistance gene? Ranking risk in resistomes
|Nature Reviews Microbiology|2014|1k